KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Gross Profit: 2017-2025

Historic Gross Profit for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $8.3 million.

  • Aquestive Therapeutics' Gross Profit fell 8.83% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.4 million, marking a year-over-year decrease of 175.86%. This contributed to the annual value of -$16.9 million for FY2024, which is 156.68% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Gross Profit is $8.3 million, which was up 52.54% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Gross Profit ranged from a high of $15.6 million in Q2 2024 and a low of -$49.2 million during Q4 2024.
  • Its 3-year average for Gross Profit is $2.8 million, with a median of $7.7 million in 2024.
  • Its Gross Profit has fluctuated over the past 5 years, first spiked by 769.57% in 2021, then tumbled by 737.05% in 2024.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Gross Profit stood at $7.7 million in 2021, then plummeted by 30.28% to $5.4 million in 2022, then spiked by 43.65% to $7.7 million in 2023, then slumped by 737.05% to -$49.2 million in 2024, then decreased by 8.83% to $8.3 million in 2025.
  • Its Gross Profit stands at $8.3 million for Q3 2025, versus $5.4 million for Q2 2025 and $5.1 million for Q1 2025.